199915-40-7

Basic information

• Product Name: 4-(4-DIETHYLAMINO-PHENYL)-THIAZOL-2-YLAMINE
• Synonyms: 4-(4-DIETHYLAMINO-PHENYL)-THIAZOL-2-YLAMINE
• CAS NO: 199915-40-7
• Molecular Formula: C13H17N3S
• Molecular Weight: 247.36
• Mol File: 199915-40-7.mol

Chemical Properties

• Boiling Point: 434.2±28.0 °C(Predicted)
• Appearance: /
• Density: 1.173±0.06 g/cm3(Predicted)
• PKA: 5.14±0.10(Predicted)
• CAS DataBase Reference: 4-(4-DIETHYLAMINO-PHENYL)-THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-DIETHYLAMINO-PHENYL)-THIAZOL-2-YLAMINE(199915-40-7)
• EPA Substance Registry System: 4-(4-DIETHYLAMINO-PHENYL)-THIAZOL-2-YLAMINE(199915-40-7)

Safety Data

• Hazardous Substances Data: 199915-40-7(Hazardous Substances Data)

Upstream product

• 207986-25-2 2-bromo-4'-(diethylamino)acetophenone 
• 199915-38-3 9-fluorenylmethoxycarbonyl isothiocyanate 
• 5520-66-1 4-(N,N-diethylamino)acetophenone 
• 17356-08-0 thiourea 

Relevant articles and documents

2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL

Compounds of formula (VIII) and compositions for treating disorders related to TRPA1 are described herein.

PYRIDO[3,4-D]PYRIMIDINYL ACETAMIDE DERIVATIVES AS TRPA1 MODULATORS

Provided are pyrido[3,4-d]pyrimidinyl acetamide derivatives as Transient Receptor Potential Ankyrin (TRPA) modulators. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Transient Receptor Potential Ankyrin 1 (TRPAl). Also provided herein are processes for preparing the compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. Formula (I).

PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS

The present invention is related to novel pyrimidinedione-fused heterocyclic compounds as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure o

UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF

The present invention provides compounds of formula (I): in which R 1, R'1, R2, R'2, R3, Y and G have the meanings given in the description, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.